Chennai, Aug 08, 2024: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Solution USP, 0.5% (Eye drops), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) TIMOPTIC, from Bausch and Lomb Inc.
Timolol Maleate Ophthalmic Solution USP, 0.5% (Eye drops) is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma. According to IQVIATM (IMS Health), Timolol Maleate Ophthalmic Solution USP, 0.5% had US sales of approximately $45 million for the 12-month period ending June 2024.